AUSTRALIAN chemotherapy compounder, Slade Health, is entering a long-term agreement with the Auckland District Health Board (ADHB) to meet the growing needs of cancer patients in the region.
The deal announced yesterday will see Slade design, build and operate a Medsafe licensed sterile compounding facility to deliver chemotherapy, antibiotics, analgesics and nutritional infusions for public and private hospitals across New Zealand.
Currently the ADHB treats 40% of the country's oncology patients, with the facility to be built to meet the local demand alongside growth in services to the wider New Zealand market, Slade Health CEO, David Slade, said.
"We are thrilled to be partnering with the ADHB to provide New Zealand hospitals and patients with a world-class compounding service," he said.
"This partnership not only marks progress for our business but also for New Zealand's health system.
"Our innovative approach will ensure the facility is designed with the latest technology to handle a broad range of formulations and clinical trials -- especially in oncology where cancer treatments are becoming more personalised and complex.
"At Slade, the patient is at the centre of everything we do.
"I am proud to say we go above and beyond to ensure critical medicines are delivered on time despite raging floods, fire, and a pandemic here in Australia.
"It is this commitment which will underpin our service in New Zealand."
The facility in Avondale, Auckland, is expected to be fully operational by mid-2022.
The above article was sent to subscribers in Pharmacy Daily's issue from 25 Jun 21
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 25 Jun 21
